[go: up one dir, main page]

MX2018008966A - Procesos mejorados para la preparacion de osimertinib (azd9291) o una sal del mismo y "azd9291 anilina" o una sal del mismo. - Google Patents

Procesos mejorados para la preparacion de osimertinib (azd9291) o una sal del mismo y "azd9291 anilina" o una sal del mismo.

Info

Publication number
MX2018008966A
MX2018008966A MX2018008966A MX2018008966A MX2018008966A MX 2018008966 A MX2018008966 A MX 2018008966A MX 2018008966 A MX2018008966 A MX 2018008966A MX 2018008966 A MX2018008966 A MX 2018008966A MX 2018008966 A MX2018008966 A MX 2018008966A
Authority
MX
Mexico
Prior art keywords
azd9291
salt
same
osimertinib
anilina
Prior art date
Application number
MX2018008966A
Other languages
English (en)
Other versions
MX378363B (es
Inventor
Alistair Boyd John
Telford Alexander
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57984913&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2018008966(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2018008966A publication Critical patent/MX2018008966A/es
Publication of MX378363B publication Critical patent/MX378363B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un proceso químico mejorado para la fabricación del compuesto de fórmula (I), que es útil, por ejemplo, como intermedio químico de las etapas finales en la producción de osimertinib (AZD9291) y sales farmacéuticamente aceptables del mismo. (ver Fórmula).
MX2018008966A 2016-02-01 2017-01-31 Procesos mejorados para la preparacion de osimertinib (azd9291) o una sal del mismo y "azd9291 anilina" o una sal del mismo. MX378363B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662289390P 2016-02-01 2016-02-01
PCT/EP2017/052050 WO2017134051A1 (en) 2016-02-01 2017-01-31 Improved process for the preparation of osimertinib (azd9291) or a salt thereof, and "azd9291 aniline" or a salt thereof

Publications (2)

Publication Number Publication Date
MX2018008966A true MX2018008966A (es) 2018-09-03
MX378363B MX378363B (es) 2025-03-10

Family

ID=57984913

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018008966A MX378363B (es) 2016-02-01 2017-01-31 Procesos mejorados para la preparacion de osimertinib (azd9291) o una sal del mismo y "azd9291 anilina" o una sal del mismo.

Country Status (18)

Country Link
US (1) US11180477B2 (es)
EP (1) EP3411038B1 (es)
JP (1) JP6812449B2 (es)
KR (1) KR102749892B1 (es)
CN (1) CN108495632B (es)
AR (1) AR107494A1 (es)
AU (1) AU2017214243B2 (es)
BR (1) BR112018014712B1 (es)
CA (1) CA3011809C (es)
CO (1) CO2018007008A2 (es)
ES (1) ES2834608T3 (es)
IL (1) IL260665B (es)
MX (1) MX378363B (es)
MY (1) MY185367A (es)
RU (1) RU2733376C2 (es)
TW (1) TWI745345B (es)
WO (1) WO2017134051A1 (es)
ZA (1) ZA201805790B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2979136T3 (es) 2016-05-26 2024-09-24 Recurium Ip Holdings Llc Compuestos inhibidores de EGFR
CN107556293B (zh) * 2017-09-19 2019-12-03 福建省微生物研究所 一种奥西替尼的合成工艺
WO2021111462A1 (en) * 2019-12-02 2021-06-10 Natco Pharma Limited An improved process for the preparation of osimertinib mesylate
US11780824B2 (en) * 2020-12-16 2023-10-10 Scinopharm Taiwan, Ltd. Process for preparing osimertinib or a salt thereof
CA3229553A1 (en) 2021-09-02 2023-03-09 Synthon B.V. A process for making osimertinib
WO2025124936A1 (en) 2023-12-15 2025-06-19 Synthon B.V. A process for making osimertinib

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4070401A (en) * 1972-02-19 1978-01-24 Mitsui Toatsu Chemicals Inc. Method for the preparation of a halogenated aromatic amine
EP2736895B1 (en) * 2011-07-27 2016-01-06 Astrazeneca AB 2-(2,4,5-substituted-anilino) pyrimidine derivatives as egfr modulators useful for treating cancer
HUE042390T2 (hu) * 2014-06-19 2019-06-28 Ariad Pharma Inc Heteroaril vegyületek kinázgátlásra
CN104817541B (zh) * 2015-05-11 2017-06-16 苏州东南药业股份有限公司 一种抗肿瘤药物的合成方法

Also Published As

Publication number Publication date
WO2017134051A1 (en) 2017-08-10
BR112018014712B1 (pt) 2023-10-31
ES2834608T3 (es) 2021-06-18
ZA201805790B (en) 2024-10-30
CO2018007008A2 (es) 2018-07-19
BR112018014712A2 (pt) 2018-12-11
KR20180101610A (ko) 2018-09-12
CA3011809C (en) 2024-02-27
RU2733376C2 (ru) 2020-10-01
TW201736364A (zh) 2017-10-16
JP6812449B2 (ja) 2021-01-13
RU2018130327A (ru) 2020-03-04
KR102749892B1 (ko) 2025-01-07
EP3411038A1 (en) 2018-12-12
US20210122734A1 (en) 2021-04-29
CN108495632A (zh) 2018-09-04
AU2017214243A1 (en) 2018-09-06
RU2018130327A3 (es) 2020-03-26
TWI745345B (zh) 2021-11-11
AR107494A1 (es) 2018-05-02
JP2019508387A (ja) 2019-03-28
US11180477B2 (en) 2021-11-23
EP3411038B1 (en) 2020-09-09
MY185367A (en) 2021-05-11
CA3011809A1 (en) 2017-08-10
IL260665B (en) 2021-08-31
MX378363B (es) 2025-03-10
AU2017214243B2 (en) 2019-07-18
CN108495632B (zh) 2021-12-31

Similar Documents

Publication Publication Date Title
PH12020551089A1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
UY37927A (es) Proceso para la preparación de 6-(2-hidroxi-2-metilpropoxi)-4-(6-(6-((6-metoxipiridin-3-il)metil)-3,6-diazabiciclo[3.1.1]heptan-3-il)piridin-3-il)pirazolo[1,5-a]piridina-3-carbonitrilo
MX2018008966A (es) Procesos mejorados para la preparacion de osimertinib (azd9291) o una sal del mismo y "azd9291 anilina" o una sal del mismo.
WO2016011390A8 (en) Irak4 inhibiting agents
MX391812B (es) Agonista fxr derivado de esteroides.
MX2018014116A (es) Procesos para la preparacion de (s)-n-(5-((r)-2-(2,5-difluorofenil )pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirroli din-1-carboxamida y sales del mismo.
MX2018014758A (es) Piridinas sustituidas con heteroarilo y metodos de uso.
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
EA201791304A1 (ru) Производные изохинолина для лечения вич
EA201791256A1 (ru) Производные хиназолина, применяемые для лечения вич
UY35567A (es) ?derivados de 3-((2s,5s)-4-metilen-5-(3- oxopropil)tetrahidrofuran-2-il)propanol, su preparación e intermediarios útiles para la misma?.
BR112019001980A2 (pt) inibidor de ido1 e método de preparação e aplicação do mesmo
AR103680A1 (es) Inhibidores selectivos de bace1
MX2015014688A (es) Tiazoles y usos de los mismos.
EA201790627A1 (ru) СТИМУЛЯТОРЫ рГЦ
PH12018501979A1 (en) Aminothiazole derivatives useful as antiviral agents
MX2016002718A (es) Derivados de ceto-imidazopiridina como moduladores del receptor huerfano relacionado con receptor retinoide (porc).
CY1124838T1 (el) Αλας παραγωγου κεφαλοσπορινης, κρυσταλλικη, στερεη μορφη αυτου και μεθοδος παραγωγης αυτου
WO2016142819A3 (en) Novel process for the preparation of ranolazine
MX2017006110A (es) Carboxamidas de quinolina para usarse en el tratamiento de leucemia.
CO2022008127A2 (es) Procesos e intermediario para la preparación de oxetan-2-ilmetanamina
CY1122375T1 (el) Συμπυκνωμενα με τετραϋδροφουρανιο αμινοϋδροθειαζινικα αναλογα τα οποια ειναι χρησιμα στη θεραπεια της νοσου toy alzheimer
PH12017500492A1 (en) Crystalline bace inhibitors
ZA201904033B (en) Pharmaceutical compounds
MX391727B (es) Modificaciones cristalinas de clorhidrato de n-(4,5-bismetansulfonil-2-metilbenzoil)guanidina y sales de n-(4,5-bismetansulfonil-2-metilbenzoil)guanidina.